Receptor-mediated low density lipoprotein catabolism in man.

Shepherd, James; Bicker, S; Lorimer, A. R.; Packard, C.J.

doi:10.1016/s0022-2275(20)40002-1

Cited by 169 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T he sam e polym orphism has also been reported to represent an independent risk factor for ischemic heart disease (15), al though there is not universal agreement on this point (16). In this study, (18,19). Such modification prevents interaction o f the lipopro tein with the receptor and denies it access to the receptor-dependent degradation pathway.…”

Section: Vldl-ldl Conversion In Hypercholesterolaemiamentioning

confidence: 61%

“…and defective cataboiism. M ost Harj L D L apoprotein synthetic rates (Table III) in excess (31)(32)(33) o f norm al values (1 1-13 mg/kg per d), whereas their total X D L FCRs lay betw een the values observed (32,33) in controls (0.35±0.06 pools/d) and those (18,31) in familial hypercholesterolem ia heterozygotes (0.19±0.046 pools/d) that have oniy a partial com plem ent of LD L receptors. T hey also ex h ib ited reduced recep to r-m e diated FC R s that varied from 9 to 39% o f the total.…”

Section: Introductionmentioning

confidence: 88%

“…Large and small VLDL of Sf 60-400 and 20-60 were radiolabeled and their metabolic fate followed in six subjects before and during bezafibrate therapy (18).…”

Section: Vldl Metabolism In Dysbetalipoproteinemiamentioning

confidence: 99%

“…The first investigations o f th e m etabolic fate o f trace-labelled V L D L in m an d e m o n stra te d [18] th at radioactivity initially p resen t in S f 10-200 " V L D L " was rapidly tra n sfe rre d to the S f 3-9 LD L density interval. L a te r w ith ap p reciatio n of the protein heterogeneity in V L D L , apo B was spe cifically exam ined and fo u n d to be the m oiety that was conserved in this process [13] in th a t all LD L apo B in the plasm a co u ld be a ttrib u…”

Section: Vldl -Ldl Conversion In Normalsmentioning

confidence: 99%

“…Plasma clearance of each tracer was followed over a 2-wk period and the radioactive decay curves were constructed and analyzed using the SAAM 29 computer program (23). This gave fractional clearance rates (FCRs) for the native and chemically m odi fied LDL that were used to obtain values for total, receptor-indepen dent, and, by difference, receptor-mediated catabolism of the lipopro tein (18,19). Plasma apo LDL concentrations were determined from calculations based on serial LDL cholesterol measurements and on com positional data derived from analyses of the isolated lipoprotein (24).…”

Section: Vldl-ldl Conversion In Hypercholesterolaemiamentioning

confidence: 99%

See 4 more Smart Citations

Genetic Determinants of Apolipoprotein B Metabolism

Demant¹

Treatment of Severe Dyslipoproteinemia in the Prevention of Coronary Heart Disease

View full text Add to dashboard Cite

Phenotyping of Apolipoprotein E Isoforms 2.3.1. Separation of apolipoproteins by isoelectric focussing 2.3.2. Western blotting of apolipoprotein E 2.4. RFLP Analysis of the Apolipoprotein B Gene 2.4.1. Preparation of DNA 2.4.2. Endonuclease digest of DNA 2.4.3. Separation of DNA fragments by agarose electrophoresis 2.4.4. Southern blotting 2.4.5. Preparation of a 32p_iabe ] _ ] _ ecj i genetic probe 2.4.6. Hybridisation of Southern filters 6 2.5. VLDL-Turnover Studies 2.5.1. Cumulative gradient ultracentrifugation 2.5.2. Preparation of radiolabelled VLDL subfractions 9 2.5.3. Analysis of apolipoprotein B in VLDL subfractions 2.5.4. Protocol for VLDL-turnovers 2.5.5. Determination of apolipoprotein B specific radioactivity 2.5.6. Determination of lipoprotein composition and 82 of pool sizes 2.5.7. Modification of the VLDL-turnover procedure for studies in patients with hyperchylomicronaemia 2.5.8. Kinetic analysis of VLDL-turnover data by the SAAM 2 9 program 2.5.9. Nutritonal records 6 2.6. LDL-Turnover Studies 2.6.1. LDL preparation by rate-zonal centrifugation 87 87 Page 2.6.2. Preparation of labelled native and cyclohexanedione modified LDL 2.6.3. Protocol for LDL-turnover studies 2.6.4. Kinetic analysis of LDL-turnover data 9 2.7. Ethical Considerations 9 2.8 Statistical Methods 8 9 2.8. Materials and Equipment 90 3. RESULTS 93 3.1. Production of a Monoclonal Antibody against 93 Apolipoprotein E 3.1.1. Preparation of apolipoprotein E 93 3.1.2. Raising of a monoclonal anti-apoE antibody 93 3.1.3. Production of antibody containing ascites 95 3.2. Apolipoprotein E Polymorphism and its 96 Correlation with Plasm Levels of Cholesterol and Apolipoprotein B 3.3. Apolipoprotein B Metabolism in Normolipidaemic 98 Subjects Homozygous for ApoE2, ApoE3 or ApoE4 3.3.1. Characterisation of study group 3.3.2. VLDL-turnover studies in apoE2/2, apoE3/3 and apoE4/4 subjects 3.3.3. Analysis of apolipoprotein B metabolism in apoE2/2, apoE3/3 and apoE4/4 subjects by computer modelling 3.4. Apolipoprotein B Metabolism in Familial Hyperchylomicronaemia 3.4.1. Characterisation of patients Page 3.4.2. VLDL-turnover studies in familial hyperchylomicronaemia 3.4.3. Computer modelling of apolipoprotein B metabolism in familial hyperchylomicronaemia 3.5. Apolipoprotein B Metabolism in Hepatic Lipase Deficiency 3.5.1. Clinical data characterising the patient 3.5.2. VLDL-turnover study in a patient with hepatic lipase deficiency 3.5.3. Computer analysis of apolipoprotein B metabolism in hepatic lipase deficiency 3.6. Apolipoprotein B Metabolism in Homozygous Familial Hypercholesterolaemia 3.6.1. Characterisation of patients 3.6.2. VLDL-turnover studies in homozygous familial hypercholesterolaemia 3.6.3. Computer analysis of apolipoprotein B metabolism in homozygous familial hyper cholesterolaemia 3.7. Apolipoprotein B Gene Polymorphisms and Lipoprotein Metabolism 3.7.1. Apolipoprotein B gene polymorphisms and plasma cholesterol levels 3.7.2. Apolipoprotein B gene polymorphisms and LDL catabolism

show abstract

Section: Vldl-ldl Conversion In Hypercholesterolaemiamentioning

confidence: 61%

Section: Introductionmentioning

confidence: 88%

“…Large and small VLDL of Sf 60-400 and 20-60 were radiolabeled and their metabolic fate followed in six subjects before and during bezafibrate therapy (18).…”

Section: Vldl Metabolism In Dysbetalipoproteinemiamentioning

confidence: 99%

Section: Vldl -Ldl Conversion In Normalsmentioning

confidence: 99%

Section: Vldl-ldl Conversion In Hypercholesterolaemiamentioning

confidence: 99%

See 3 more Smart Citations